Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | TOP1 | P11387 | 3/20 | 0.58 |
| ▸ | TOP2A | P11388 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | TERT | O14746 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | BLM | P54132 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 2/20 | 0.53 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.53 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14669385 | 0.99 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2TOP1TOP2AHPGD | |
| SCHEMBL14892811 | 0.96 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2TOP1TOP2AHPGD | |
| SCHEMBL13528291 | 0.91 | SMN1; SMN2 (0.57) | ALDH1A1SMN1; SMN2TOP1TOP2AHPGD | |
| SCHEMBL933054 | 0.91 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2TOP1TOP2AHPGD | |
| SCHEMBL14892248 | 0.87 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2TOP1TOP2AHPGD | |
| SCHEMBL6530109 | 0.86 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2TOP1TOP2AHPGD | |
| SCHEMBL14892180 | 0.86 | TERT (0.54) | ALDH1A1SMN1; SMN2TOP1TOP2AHPGD | |
| SCHEMBL14665724 | 0.86 | TERT (0.49) | ALDH1A1SMN1; SMN2TOP1TOP2AHPGD | |
| SCHEMBL2554887 | 0.86 | LGMN (0.48) | ALDH1A1SMN1; SMN2TOP1TOP2AHPGD | |
| SCHEMBL14669422 | 0.86 | PARP1 (0.44) | ALDH1A1SMN1; SMN2TOP1TOP2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590332-B1 | A PROCESS FOR THE SYNTHESIS OF BISBENZIMIDAZOLES AND THEIR DERIVATIVES. | UNIV DELHI (IN) | 2011-04-27 | — | — | EP | claimed |
| US-20210324198-A1 | SILICON-SUBSTITUTED RHODAMINE DYES AND DYE CONJUGATES | Life Technologies Corporation | 2021-10-21 | — | — | US | disclosed |
| CN-106866635-B | PLK1 inhibitor and preparation method and application thereof | 深圳先进技术研究院 | 2020-06-05 | — | — | CN | disclosed |
| CN-106674209-B | Programmed death receptor 1 gene inhibitor and preparation method and application thereof | 深圳先进技术研究院 | 2020-03-06 | — | — | CN | disclosed |
| WO-2020033681-A2 | SILICON-SUBSTITUTED RHODAMINE DYES AND DYE CONJUGATES | Life Technologies Corporation (US) | 2020-02-13 | — | — | WO | disclosed |
| US-RE46943-E1 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2018-07-10 | — | — | US | disclosed |
| US-RE46943-E1 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2018-07-10 | — | — | US | disclosed |
| US-RE46943-E1 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2018-07-10 | — | — | US | disclosed |
| EP-2591795-B1 | RNA targeting compounds and methods for making and using same | UNIV NEW YORK STATE RES FOUND (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-2556058-B1 | RADIOPROTECTOR COMPOUNDS AND METHODS | PETER MACCALLUM CANCER INST (AU) | 2017-06-14 | — | — | EP | disclosed |
| EP-2129388-B1 | RNA TARGETING COMPOUNDS AND METHODS FOR MAKING AND USING SAME | UNIV NEW YORK STATE RES FOUND | 2012-09-12 | — | — | EP | disclosed |
| EP-1590332-B1 | A PROCESS FOR THE SYNTHESIS OF BISBENZIMIDAZOLES AND THEIR DERIVATIVES. | UNIV DELHI (IN) | 2011-04-27 | — | — | EP | disclosed |
| EP-1590332-B1 | A PROCESS FOR THE SYNTHESIS OF BISBENZIMIDAZOLES AND THEIR DERIVATIVES. | UNIV DELHI (IN) | 2011-04-27 | — | — | EP | disclosed |
| US-20080227213-A1 | Comprising polymer backbone and two or more pendant RNA binding ligands; myotonic dystrophy | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE | 2008-09-18 | — | — | US | disclosed |
| WO-2007045096-A1 | OLIGOHETEROAROMATIC LUMINISCENT ASSEMBLIES AS HIGH-AFFINITY DNA SEQUENCE-DIRECTED LIGANDS | UNIVERSITY OF SASKATCHEWAN (CA) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007016455-A2 | COMPOSITIONS AND METHODS USING AMINOGLYCOSIDES TO BIND DNA AND RNA | CLEMSON UNIVERSITY RESEARCH FOUNDATION (US) | 2007-02-08 | — | — | WO | disclosed |
| EP-1590332-A1 | A PROCESS FOR THE SYNTHESIS OF BISBENZIMIDAZOLES AND ITS DERIVATIONS | University of Delhi (IN) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004063170-A1 | A PROCESS FOR THE SYNTHESIS OF BISBENZIMIDAZOLES AND ITS DERIVATIONS | UNIVERSITY OF DELHI (IN) | 2004-07-29 | — | — | WO | disclosed |
| US-6548505-B1 | Protecting biological materials from damage caused by radiation; side effect reduction during radiotherapy or chemotherapy; indole, benzimidazole, benzoxazole or benzothiazole compounds substituted with 4-alkylpiperazino | PETER MACCALLUM CANCER INSTITUTE (AU) | 2003-04-15 | — | — | US | disclosed |
| US-6194414-B1 | CANCER THERAPY; PREVENT RADIATION DAMAGE | THE INNER AND EASTERN HEALTH CARE NETWORK (AU) | 2001-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210324198-A1 | SILICON-SUBSTITUTED RHODAMINE DYES AND DYE CONJUGATES | SRI, SI, IK | ALDH1A1 1849/4885SMN1; SMN2 2012/4885TOP1 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.